Autologous osteoblastic cell therapy - Bone Therapeutics

Drug Profile

Autologous osteoblastic cell therapy - Bone Therapeutics

Alternative Names: Autologous-osteoblastic-cells-Bone-Therapeutics; Autologous-pre-osteoblast-cell-therapy-Bone-Therapeutics; Autologous-pre-osteoblastic-cell-therapy-Bone-Therapeutics; Autologous-preosteoblastic-cells-Bone-Therapeutics; PREOB; PREOB cells

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bone Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Femur head necrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Femur head necrosis
  • Phase II/III Non-union fracture
  • Phase II Osteoporosis

Most Recent Events

  • 20 Oct 2017 Bone Therapeutics terminates a phase II/III trial in Non-union fracture in Belgium and Netherlands to focus resources in the allogeneic platform and provide optimal value for patients (Intraosseous) (NCT01756326)
  • 22 Sep 2017 Autologous osteoblastic cell therapy licensed to Asahi Kasei in Japan
  • 16 Sep 2016 Efficacy data from a clinical trial in Femur head necrosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research-2016 (ASBMR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top